GRABAR LAW OFFICE INVESTIGATES POTENTIAL CLAIMS AGAINST OFFICERS AND DIRECTORS OF NATERA, INC. (NASDAQ: NTRA)
Grabar Law Office is investigating potential claims on behalf of Natera, Inc. (NASDAQ: NTRA) shareholders. The investigation concerns whether certain officers of Natera have breached their fiduciary duties owed to the company.
Natera, Inc. offers genetic testing in the areas of women’s health, oncology, and organ health. Among other things, the Company produces and markets Panorama (a NIPT) and Prospera (which screens for kidney transplant failure). The Company’s technology evaluates single nucleotide polymorphisms (“SNPs”), the most common type of genetic variation among people.
A federal securities fraud complaint has been filed that alleges that Natera, through certain of its officers, misrepresented and/or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants’ false and misleading claims about Natera’s technology, the company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.
Current Natera shareholders who have held Natera stock since before February 26, 2020, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, you are encouraged to contact us at firstname.lastname@example.org, or call Joshua Grabar at 267-507-6085.